Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745)
versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and
oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.